Reference is made to the stock exchange announcement made by Inify Laboratories AB (the "Company") on 4 December 2025 regarding the resolution to issue 26,266,866 new shares in a private placement (the "Private Placement Shares") and 2,304,563 new shares in a repair issue (the "Repair Issue Shares").

The share capital increase pertaining to the issuance of the Private Placement Shares and the Repair Issue Shares has now been registered with the Swedish Companies Registration Office (Sw. Bolagsverket). The Company's new registered share capital is SEK 6,945,746.803089, divided on 107,474,845 shares, each with a nominal value of SEK 0.064627.

The Private Placement Shares and the Repair Issue Shares are, subject to timely payment, expected to be delivered on or about 30 March 2026.

Delivery of shares to Auris AS

The 72,508 Private Placement Shares and the 149,701 Repair Issue Shares that are allocated to Auris AS under its guarantee undertaking will, pursuant to a request from Auris AS, be delivered to Tauri AS. Auris AS and Tauri AS are companies ultimately owned by the same person.

Advisors

SB1 Markets AS has been appointed as financial advisor in connection with the private placement and the repair issue. Schjødt law firm acts as legal counsel to the Company.

For further information, please contact CEO, Fredrik Palm, fredrik.palm@inify.com, or visit https://www.inify.com.  

###

This information is subject to the disclosure requirements pursuant to section 5-12 the Norwegian Securities Trading Act.

###

The future of diagnostics

Inify Laboratories offers diagnostics through specialised laboratory services in histopathology, with a focus on streamlining patient pathways. The company performs clinical diagnostics in prostate cancer and gastroenterology, providing an integrated service that spans from early sample handling to final diagnosis.  The laboratory system is scalable both in handling large volumes of patient samples and for replicating in new locations.

Quality and response times are optimised in every step - from logistics to tissue preparation and diagnosis - using a fully digital, standardised and AI-assisted workflow. The diagnosis is always performed by a pathologist and is assisted by Inify's proprietary AI, proven to have world-leading precision in clinical evaluations. The entire workflow is supported by a tailor-made system that also enables development to include additional diagnostic areas.

Inify Laboratories is an international group headquartered in Solna, Sweden, with local laboratories in Sweden and the UK. The company's share is listed on Euronext Growth Oslo under the ticker INIFY.